Vaccibody CEO Bonde: Make Undefeatable Diseases Defeatable
This article was originally published in Scrip
Norway-based vaccine company, Vaccibody, has recently begun the first stage of clinical trials with its immunotherapy VB10.16 for patients with cervical intraepithelial neoplasia (CIN 2/3). Dr. Martin Bonde, a biotech veteran who sold EpiTherapeutics ApS to Gilead Sciences Inc. earlier this year for $65m, is now its CEO. He tells Scrip about his new challenge to use Vaccibody's unique technology to treat CIN and make undefeatable diseases defeatable.